Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature

Nathaniel E Wiest; Katherine S Tzou; Matthew T Olson; Steven M Herchko; Essa M Bajalia; David D Thiel; Yanyan Lou; Yujie Zhao; Rami Manochakian

doi:10.1002/ccr3.4278

Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature

Clin Case Rep. 2021 Jun 10;9(6):e04278. doi: 10.1002/ccr3.4278. eCollection 2021 Jun.

Authors

Nathaniel E Wiest¹, Katherine S Tzou², Matthew T Olson³, Steven M Herchko², Essa M Bajalia⁴, David D Thiel⁴, Yanyan Lou⁵, Yujie Zhao⁵, Rami Manochakian⁵

Affiliations

¹ Department of Internal Medicine Mayo Clinic Florida Jacksonville FL USA.
² Department of Radiation Oncology Mayo Clinic Florida Jacksonville FL USA.
³ Roche Diagnostics Tucson AZ USA.
⁴ Department of Urology Mayo Clinic Florida Jacksonville FL USA.
⁵ Division of Hematology/Oncology Department of Medicine Mayo Clinic Florida Jacksonville FL USA.

Abstract

Non-small cell lung cancer patients with anaplastic lymphoma kinase or c-ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib-associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression-free survival.

Keywords: ALK positive; crizotinib; non‐small‐cell lung cancer; progression‐free survival; renal cysts.

Publication types

Case Reports